410 related articles for article (PubMed ID: 24458078)
1. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
[TBL] [Abstract][Full Text] [Related]
2. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
.
Macdougall IC; Strauss WE; Dahl NV; Bernard K; Li Z
Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204
[TBL] [Abstract][Full Text] [Related]
3. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
[TBL] [Abstract][Full Text] [Related]
4. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy.
Hetzel D; Strauss W; Bernard K; Li Z; Urboniene A; Allen LF
Am J Hematol; 2014 Jun; 89(6):646-50. PubMed ID: 24639149
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
[TBL] [Abstract][Full Text] [Related]
6. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
7. Ferumoxytol: an intravenous iron, riskier than iron sucrose.
Prescrire Int; 2013 Sep; 22(141):206. PubMed ID: 24171212
[No Abstract] [Full Text] [Related]
8. Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study.
Abdel-Razeq H; Abbasi S; Saadi I; Jaber R; Abdelelah H
Drug Des Devel Ther; 2013; 7():939-44. PubMed ID: 24039403
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.
Schiller B; Bhat P; Sharma A
Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of intravenous and oral iron in chronic kidney disease.
Agarwal R; Kusek JW; Pappas MK
Kidney Int; 2015 Oct; 88(4):905-14. PubMed ID: 26083656
[TBL] [Abstract][Full Text] [Related]
11. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
Onken JE; Bregman DB; Harrington RA; Morris D; Buerkert J; Hamerski D; Iftikhar H; Mangoo-Karim R; Martin ER; Martinez CO; Newman GE; Qunibi WY; Ross DL; Singh B; Smith MT; Butcher A; Koch TA; Goodnough LT
Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731
[TBL] [Abstract][Full Text] [Related]
12. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.
Provenzano R; Schiller B; Rao M; Coyne D; Brenner L; Pereira BJ
Clin J Am Soc Nephrol; 2009 Feb; 4(2):386-93. PubMed ID: 19176796
[TBL] [Abstract][Full Text] [Related]
13. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.
Kowalczyk M; Banach M; Rysz J
J Nephrol; 2011; 24(6):717-22. PubMed ID: 21956770
[TBL] [Abstract][Full Text] [Related]
14. Review of available intravenous iron preparations in hemodialysis.
Palmer K; Cameron K; Battistella M
CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
[No Abstract] [Full Text] [Related]
15. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients.
Fishbane S; Bolton WK; Winkelmayer WC; Strauss W; Li Z; Pereira BJ
Clin Nephrol; 2012 Sep; 78(3):181-8. PubMed ID: 22874106
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
Goldstein SL; Morris D; Warady BA
Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582
[TBL] [Abstract][Full Text] [Related]
17. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
Bhandari S; Kalra PA; Kothari J; Ambühl PM; Christensen JH; Essaian AM; Thomsen LL; Macdougall IC; Coyne DW
Nephrol Dial Transplant; 2015 Sep; 30(9):1577-89. PubMed ID: 25925701
[TBL] [Abstract][Full Text] [Related]
18. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.
Lu M; Cohen MH; Rieves D; Pazdur R
Am J Hematol; 2010 May; 85(5):315-9. PubMed ID: 20201089
[TBL] [Abstract][Full Text] [Related]
19. Ferumoxytol for treating iron deficiency anemia in CKD.
Spinowitz BS; Kausz AT; Baptista J; Noble SD; Sothinathan R; Bernardo MV; Brenner L; Pereira BJ
J Am Soc Nephrol; 2008 Aug; 19(8):1599-605. PubMed ID: 18525001
[TBL] [Abstract][Full Text] [Related]
20. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
Womack R; Berru F; Panwar B; Gutiérrez OM
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
